Semaglutide vs. Tirzepatide:
How to Choose.

The Fundamental Difference

Both semaglutide and tirzepatide are weekly injectable GLP-1 receptor agonists used for weight loss and metabolic health. The core difference is the number of receptors they target. Semaglutide is a GLP-1 receptor agonist — it activates one receptor. Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates two. That second receptor, GIP, changes the pharmacology in ways that matter clinically.

GIP (glucose-dependent insulinotropic polypeptide) is another incretin hormone released after meals. Adding GIP agonism appears to amplify the appetite-suppressing effects of GLP-1, improve tolerability at higher doses, and drive greater fat loss. The real-world result: tirzepatide produces, on average, greater weight loss than semaglutide — roughly 20% versus 15% in head-to-head trial data.

Semaglutide: What You Need to Know

Semaglutide is the active ingredient in Ozempic (approved for type 2 diabetes) and Wegovy (approved for chronic weight management). It is the most studied GLP-1 medication in the world, with clinical trial data going back nearly a decade. The STEP 1 trial — the landmark weight loss study — showed 14.9% average body weight reduction over 68 weeks in adults with obesity.

Semaglutide is available as a compounded injectable through 503B-regulated pharmacies, making it accessible at a significantly lower cost than brand-name Ozempic or Wegovy. The compounded version uses the same active molecule, produced under FDA-regulated conditions, with the same clinical mechanism.

It is an appropriate starting point for most patients — particularly those who are new to GLP-1 therapy, have a history of GI sensitivity, or want to begin at a more conservative titration schedule before considering a higher-potency option.

Tirzepatide: What You Need to Know

Tirzepatide is the active ingredient in Mounjaro (approved for type 2 diabetes) and Zepbound (approved for chronic weight management). It is newer than semaglutide, with the landmark SURMOUNT-1 trial published in 2022 showing an average of 20.9% body weight reduction at the highest dose over 72 weeks — with some participants losing more than 25%.

The addition of GIP agonism appears to improve how tirzepatide is tolerated at higher doses, meaning patients can often reach the maximum dose with less nausea than comparable semaglutide doses. This tolerability advantage is clinically meaningful — it is one reason tirzepatide can drive greater weight loss even though the side effect profile is not dramatically worse.

Compounded tirzepatide access is more limited than semaglutide. Availability depends on regulatory status at the time of your consultation. A licensed provider can advise on current access and appropriate candidacy.

Head to Head: An Honest Comparison

How to Actually Choose

For most patients beginning a GLP-1 protocol, compounded semaglutide is the appropriate starting point. It has the deepest clinical evidence base, the widest compounding access, and a well-established titration protocol. If you respond well and want to optimize further — or if your weight loss goals are more aggressive — tirzepatide becomes the logical next conversation.

Patients who have tried semaglutide and plateaued, or those with a BMI significantly above 35 who want to maximize outcomes from the start, may be better candidates for tirzepatide immediately. That determination is made in a clinical consultation — not by a website.

What matters more than which molecule you choose is that you are using a properly sourced compound, working with a licensed provider, and following a titration schedule designed for your physiology. The best GLP-1 drug is the one you can tolerate, access consistently, and use under appropriate clinical oversight.